Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + a quinone
1-(beta-D-ribofuranosyl)nicotinamide + a hydroquinone
-
-
-
-
?
1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + a quinone
1-(beta-D-ribofuranosyl)nicotinamide + a quinol
-
-
-
?
1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + co-enzyme Q
1-(beta-D-ribofuranosyl)nicotinamide + reduced co-enzyme Q
-
natural substrate nicotinamide riboside, NRH
-
-
?
1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + menadione
1-(beta-D-ribofuranosyl)nicotinamide + menadiol
1-(carbamoylmethyl)dihydronicotinamide + 3-hydroxy-1-methylindoline-5,6-dione
1-(carbamoylmethyl)nicotinamide + 3-hydroxy-1-methylindoline-5,6-diol
-
3-hydroxy-1-methylindoline-5,6-dione i.e. adrenochrome
-
-
?
1-benzyl-1,4-dihydronicotinamide + estradiol-3,4-quinone
1-benzyl-3-carbamoylpyridinium + estrone-3,4-quinone
-
-
-
-
r
1-carbamoylmethyl-3-carbamoyl-1,4-dihydropyrimidine + menadione
1-carbamoylmethyl-3-carbamoylpyrimidine + menadiol
-
-
-
?
17beta-17-hydroxyestr-1(10)-ene-3,4-dione + N-benzyldihydronicotinamide
17beta-estra-1(10),2,4-triene-3,4,17-triol + N-benzylnicotinamide
-
ping-pong mechanism, NQO2 is faster in reducing estrogen quinones than its homologue NQO1
-
-
?
2,6-dichloroindophenol + dihydronicotinamide riboside
?
-
-
-
?
2,6-dichloroindophenol + dihydronicotinamide riboside
? + nicotinamide riboside
2H-dibenzo[b,f]azepin-2-one + dihydronicotinamide riboside
? + nicotinamide riboside
-
-
-
?
5-(aziridin-1-yl)-2,4-dinitrobenzamide + dihydronicotinamide riboside
? + nicotinamide riboside
-
-
-
?
5-(aziridin-1-yl)-2,4-dinitrobenzamide + menadiol
? + reduced menadiol
-
-
-
-
?
amodiaquine quinone imine + dihydronicotinamide riboside
? + nicotinamide riboside
-
-
-
?
benzo(a)pyrene-3,6-quinone + dihydronicotinamide riboside
? + nicotinamide riboside
-
-
-
?
desethylamodiaquine quinone imine + dihydronicotinamide riboside
? + nicotinamide riboside
-
-
-
?
diclofenac-1',4'-quinone imine + dihydronicotinamide riboside
? + nicotinamide riboside
-
-
-
?
diclofenac-2,5-quinone imine + dihydronicotinamide riboside
? + nicotinamide riboside
-
-
-
?
dihydrobenzylnicotinamide + menadione
?
-
-
-
-
?
dihydronicotinamide riboside + 2,6-dichlorophenolindophenol
nicotinamide riboside + reduced 2,6-dichlorophenolindophenol
-
-
-
-
?
dihydronicotinamide riboside + 3-(4,5-dimethylthiazaol-2-yl)-2,5-diphenyltetrazolium
nicotinamide riboside + ?
-
-
-
-
?
dihydronicotinamide riboside + CB 1954
nicotinamide riboside + ?
-
-
-
-
?
dihydronicotinamide riboside + menadione
ribosyl nicotinamide + menadiol
-
-
-
-
?
dihydronicotinamide riboside + menadione/3-(4,5-dimethylthiazaol-2-yl)-2,5-diphenyltetrazolium
nicotinamide riboside + ?
-
-
-
-
?
dihydronicotinamide riboside + methyl red
nicotinamide riboside + ?
-
-
-
-
?
estrone-3,4-quinone + N-benzyldihydronicotinamide
estrone-3,4-quinol + N-benzylnicotinamide
-
ping-pong mechanism, NQO2 is faster in reducing estrogen quinones than its homologue NQO1
-
-
?
mefenamic acid-1',4'-quinone imine + dihydronicotinamide riboside
? + nicotinamide riboside
-
-
-
?
mefenamic acid-2,5-quinone imine + dihydronicotinamide riboside
? + nicotinamide riboside
-
-
-
?
menadione + 1-(2-hydroxyethyl)dihydronicotinamide
?
-
-
-
?
menadione + 1-benzyl-1,4-dihydronicotinamide
?
-
-
-
?
menadione + dihydrobenzylnicotinamide
?
menadione + dihydronicotinamide riboside
menadiol + nicotinamide riboside
-
-
-
?
mitomycin C + dihydronicotinamide riboside
? + nicotinamide riboside
-
-
-
?
N-acetyl-p-benzoquinone imine + dihydronicotinamide riboside
? + nicotinamide riboside
-
-
-
?
N-benzyldihydronicotinamide + 2,6-dichlorophenolindophenol
N-benzylnicotamide + reduced 2,6-dichlorophenolindophenol
-
-
-
?
N-benzyldihydronicotinamide + 2,6-dichlorophenolindophenol
N-benzylnicotinamide + reduced 2,6-dichlorophenolindophenol
-
-
-
-
?
N-benzyldihydronicotinamide + a quinone
N-benzylnicotinamide + a hydroquinone
-
synthetic substrate
-
-
?
N-benzyldihydronicotinamide + coenzyme Q0
?
-
-
-
-
?
N-benzyldihydronicotinamide + coenzyme Q0
N-benzylnicotinamide + ?
-
-
-
-
?
N-benzyldihydronicotinamide + coenzyme Q1
N-benzylnicotinamide + ?
-
-
-
-
?
N-benzyldihydronicotinamide + menadione
?
N-benzyldihydronicotinamide + menadione
N-benzylnicotamide + menadiol
-
-
-
-
?
N-benzyldihydronicotinamide + menadione
N-benzylnicotinamide + menadiol
-
-
-
-
?
N-benzyldihydronicotinamide + oxidized coenzyme Q0
N-benzylnicotinamide + reduced coenzyme Q20
-
-
-
-
?
N-benzyldihydronicotinamide + oxidized coenzyme Q1
N-benzylnicointamide + reduced coenzyme Q1
-
-
-
-
?
N-benzyldihydronicotinamide + oxidized coenzyme Q2
N-benzylnicotinamide + reduced coenzyme Q2
-
-
-
-
?
N-benzylnicotinamide + menadiol
?
-
-
-
-
?
N-methyldihydronicotinamide + 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
N-methylnicotinamide + ?
-
-
-
-
?
N-methyldihydronicotinamide + 3-hydroxy-1-methylindoline-5,6-dione
N-methylnicotinamide + 3-hydroxy-1-methylindoline-5,6-diol
-
3-hydroxy-1-methylindoline-5,6-dione i.e. adrenochrome. When NADH is used as the electron donor, quinone reductase 2 possesses no activity for the reduction of adrenochrome
-
-
?
N-methyldihydronicotinamide + menadione
?
N-methyldihydronicotinamide + menadione
N-methylnicotinamide + menadiol
N-ribosylnicotinamide + menadiol
?
-
N-ribosylnicotinamide is a poor substrate
-
-
?
NADH + 2,6-dichlorophenolindophenol
?
-
-
-
-
r
nicotinamide riboside + menadiol
dihydronicotinamide riboside + menadione
-
-
-
-
?
nicotinamide riboside + reduced 2,6-dichlorophenolindophenol
dihydronicotinamide riboside + 2,6-dichlorophenolindophenol
-
-
-
-
?
nicotinamide riboside + reduced coenzyme Q0
dihydronicotinamide riboside + coenzyme Q0
-
-
-
-
?
nicotinamide riboside + reduced coenzyme Q1
dihydronicotinamide riboside + coenzyme Q1
-
-
-
-
?
nicotinamide riboside + reduced coenzyme Q2
dihydronicotinamide riboside + coenzyme Q2
-
-
-
-
?
reduced N-methyldihydronicotinamide + menadione
? + menadiol
-
-
-
-
?
reduced N1-(benzyl)-nicotinamide + menadione
N1-(benzyl)-nicotinamide + menadiol
-
-
-
-
?
reduced N1-(methyl)-nicotinamide + menadione
N1-(methyl)-nicotinamide + reduced menadiol
-
-
-
-
?
reduced N1-(n-propyl)-nicotinamide + menadione
N1-(n-propyl)-nicotinamide + menadiol
-
-
-
-
?
tetrahydrofolate + menadiol
?
-
-
-
-
?
additional information
?
-
1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + menadione
1-(beta-D-ribofuranosyl)nicotinamide + menadiol
-
-
-
-
?
1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + menadione
1-(beta-D-ribofuranosyl)nicotinamide + menadiol
-
natural substrate nicotinamide riboside, NRH
-
-
?
2,6-dichloroindophenol + dihydronicotinamide riboside
? + nicotinamide riboside
-
-
-
?
2,6-dichloroindophenol + dihydronicotinamide riboside
? + nicotinamide riboside
-
-
-
?
menadione + dihydrobenzylnicotinamide
?
-
-
-
-
?
menadione + dihydrobenzylnicotinamide
?
-
-
-
-
?
N-benzyldihydronicotinamide + menadione
?
-
-
-
-
?
N-benzyldihydronicotinamide + menadione
?
-
-
-
-
?
N-methyldihydronicotinamide + menadione
?
-
-
-
-
?
N-methyldihydronicotinamide + menadione
?
-
-
-
?
N-methyldihydronicotinamide + menadione
N-methylnicotinamide + menadiol
-
-
-
-
?
N-methyldihydronicotinamide + menadione
N-methylnicotinamide + menadiol
-
-
-
?
additional information
?
-
-
no activity with NADH, NADPH, NMNH, reduced 3-acetylpyridine adenine dinucleotide, xanthine or hypoxanthine. No activity with 1,4-benzoquinone and potassium ferricyanide
-
-
?
additional information
?
-
-
enzyme exhibits melatonin-binding activity
-
-
?
additional information
?
-
high QR2 activity might make individuals more susceptible to Parkinsons disease. By inhibiting QR2, it seems that anti-malarial compounds such as quinacrine favour the red blood cell oxidative stress leading to the death of the parasite
-
-
?
additional information
?
-
knockdown K562 cells exhibit increased antioxidant and detoxification enzyme expression and reduced proliferation rates
-
-
?
additional information
?
-
-
the expression of the NQO2 gene is induced in response to 2,3,7,8-tetrachlorodibenzo-p-dioxin
-
-
?
additional information
?
-
enzyme cannot use NADH or NADPH as reducing agent
-
-
?
additional information
?
-
-
no activity with one-electron acceptors such as potassium ferricyanide
-
-
?
additional information
?
-
-
the D allele in the promoter is associated with higher NQO2 activity and increases levels of ROS in the presence of dopamine, which would then increase susceptibility to Parkinson's disease
-
-
?
additional information
?
-
-
NQO2 catalyzes the reduction of electrophilic estrogen quinones and thereby may act as a detoxification enzyme
-
-
?
additional information
?
-
-
the enzyme does not accept conventional phosphorylated nicotinamides as hydride donors
-
-
?
additional information
?
-
-
NQO2 can function as a nitroreductase in activating the antitumor drug 5-aziridinyl-2,4-dinitrobenzamide
-
-
?
additional information
?
-
-
the enzyme catalyzes the reduction of quinones, such as menadione and co-enzyme Q
-
-
?
additional information
?
-
-
QR2 produces free radicals with pro-drug CB1954, i.e. 5-(aziridin-1-yl)-2,4-dinitrobenzamide. The anti-cancer pro-drug CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide) is transformed into a potent cytotoxic drug upon reduction of its 4-nitro group to a 4-hydroxylamine by quinone reductases or nitroreductase
-
-
?
additional information
?
-
-
quinone reductase 2 (QR2) is implicated in the reduction of quinone in the presence of natural derivatives of NADH such as N-ribosyldihydronicotinamide. QR2 does not recognize NADH or NADPH as co-substrates, unlike quinone reductase 1 (QR1)
-
-
?
additional information
?
-
no substrate: 5-hydroxydiclofenac quinone imine
-
-
-
additional information
?
-
-
no substrate: 5-hydroxydiclofenac quinone imine
-
-
-
additional information
?
-
-
enzyme exhibits melatonin-binding activity
-
-
?
additional information
?
-
-
by deleting QR2 it seems that mice become increasingly susceptible to polycyclic aromatic hydrocarbon-induced skin carcinogenesis
-
-
?
additional information
?
-
-
organs of mice deleted for NQO2 are depleted of MT3 binding sites. NQO2 is part of the melatonin receptor MT3 binding sites
-
-
?
additional information
?
-
-
quinone reductase 2 is a target of resveratrol in vascular smooth muscle cells. Resveratrol reduces quinone reductase protein levels and suppresses quinone reductase 2 mRNA expression in cultured vascular smooth muscle cell. The inhibition of vascular smooth muscle cell proliferation by resveratrol is effected via the negative regulation of quinone reductase 2. Quinone reductase 2 may be the main target for resveratrol and may be used to mediate the potential therapeutic role of resveratrol in atherosclerosis and restenosis after injury
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(E)-3-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)acrylaldehyde
-
-
(E)-3-(3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)prop-2-en-1-ol
-
-
(Z)-3-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)-acrylamide
-
-
(Z)-3-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)acrylonitrile
-
-
(Z)-3-(3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)acrylaldehyde
-
-
(Z)-3-(3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)acrylonitrile
-
-
(Z)-5-(3-hydroxy-2-(4-hydroxyphenyl)prop-1-en-1-yl)benzene-1,3-diol
-
-
1,1'-(1E)-but-1-ene-1,2-diylbis(3,5-dimethoxybenzene)
-
-
1,2-dimethoxy-4-[(1E)-2-(4-methoxyphenyl)prop-1-en-1-yl]benzene
-
-
1,2-dimethoxy-4-[(E)-2-(3-methoxyphenyl)ethenyl]benzene
-
-
1,2-dimethoxy-4-{(1Z)-3,3,3-trifluoro-2-[3-(trifluoromethyl)phenyl]prop-1-en-1-yl}benzene
-
-
1,3-dimethoxy-5-[(1E)-2-(4-methoxyphenyl)prop-1-en-1-yl]benzene
-
-
1,3-dimethoxy-5-[(1Z)-3,3,3-trifluoro-1-(4-methoxyphenyl)prop-1-en-2-yl]benzene
-
-
1,3-dimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]benzene
-
-
1,4-dimethylphenanthrene
-
0.00001 mM, 15% inhibition of the reaction with N1-(n-propyl)-nicotinamide
1,4-dimethylquinolin-2(1H)-one
-
-
1-[(E)-2-(4-fluorophenyl)ethenyl]-3,5-dimethoxybenzene
-
-
12-methylbenz[a]anthracene
-
0.00001 mM, 51% inhibition of the reaction with N1-(n-propyl)-nicotinamide
2-(2-methoxy-6H-pyrido[2',3':4,5]pyrrolo[2,1-a]isoindol-11-yl)ethylamine
-
IC50: 0.00087 mM
2-hydroxyestradiol
-
0.01 mM, 17% inhibition
2-iodo-5-methoxycarbonylamino-N-acetyltryptamine
-
-
2-iodo-melatonin
-
IC50: 0.016 mM
2-methoxy-6-((2-(6-methoxy-2-methylquinolin-4-yl)hydrazono)methyl)phenol
-
-
2-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]naphthalene
-
-
2-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]naphthalene
-
-
3-[(Z)-(6-methoxy-2-methylquinolin-4-yl)diazenyl]phenol
-
-
3-{[4-(dihydroxyamino)phenoxy]methyl}-5-methoxy-1,2-dimethyl-1H-indole-4,7-dione
-
-
4',5,7-trihydroxyflavone
-
0.01 mM, 61% inhibition
4-(5-phenyl-1,3-oxazol-2-yl)benzene-1-carboximidamide
-
inhibits the growth of Plasmodium falciparum with an IC50 value of 0.3 microM
-
4-(5-phenylfuran-2-yl)benzene-1-carboximidamide
-
-
4-(5-phenylthiophen-2-yl)benzene-1-carboximidamide
-
-
4-hydroxyestradiol
-
0.01 mM, 18% inhibition
4-hydroxyestrone
-
0.01 mM, 22% inhibition
4-[(1E)-1-(3,5-dimethoxyphenyl)prop-1-en-2-yl]-1,2-dimethoxybenzene
-
-
4-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-N,N-dimethylaniline
-
-
4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]-1,2-dimethoxybenzene
-
-
4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol
-
-
4-[(E)-2-(3-fluorophenyl)ethenyl]benzene-1,2-diol
-
-
4-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,2-diol
-
-
4-[(E)-2-(4-methoxyphenyl)ethenyl]benzene-1,2-diol
-
-
4-[(Z)-(1H-imidazol-4-yl)diazenyl]-6-methoxy-2-methylquinoline
-
-
4-[(Z)-(4-fluorophenyl)diazenyl]-6-methoxy-2-methylquinoline
-
-
4-[(Z)-(6-methoxy-2-methylquinolin-4-yl)diazenyl]benzoic acid
-
-
4-[(Z)-(6-methoxy-2-methylquinolin-4-yl)diazenyl]phenol
-
-
4-[(Z)-benzyldiazenyl]-6-methoxy-2-methylquinoline
-
-
4-[(Z)-[(1H-imidazol-4-yl)methyl]diazenyl]-6-methoxy-2-methylquinoline
-
-
4-{(1E)-1-[4-(trifluoromethyl)phenyl]prop-1-en-2-yl}phenol
-
-
4-{(E)-2-[3-(trifluoromethyl)phenyl]ethenyl}benzene-1,2-diol
-
-
5,6,8-trimethoxy-1,4-dimethylquinolin-2(1H)-one
-
-
5,6,8-trimethoxy-4-methylquinolin-2(1H)-one
-
-
5,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one
-
-
5,8-dimethoxy-4-methylquinolin-2(1H)-one
-
-
5-(2-(dimethylamino)ethylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(2-(dimethylamino)ethylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one N-oxide
-
5-(2-(dimethylamino)ethylamino)-8-bromo-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(2-(dimethylamino)ethylamino)-8-bromo-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one N-oxide
-
5-(2-(dimethylamino)ethylamino)-8-fluoro-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(2-(dimethylamino)ethylamino)-8-methoxy-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(2-(dimethylamino)ethylamino)-8-methoxy-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one N-oxide
-
5-(3-hydroxypropylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(3-hydroxypropylamino)-8-bromo-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(3-hydroxypropylamino)-8-methoxy-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(4-methoxyphenylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(isopentylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-(phenethylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
5-amino-1,2-dimethyl-3-[(2,4,6-trifluorophenoxy)methyl]-1H-indole-4,7-dione
-
-
5-hydroxyflavone
-
IC50: 340 nM
5-methoxy-carbonylamino-N-acetyltryptamine
-
IC50: 0.295 mM
5-methoxycarbonylamino-N-acetyltryptamine
5-[(1E)-1-(4-hydroxyphenyl)prop-1-en-2-yl]benzene-1,3-diol
-
-
5-[(1E)-2-(3,4-dimethoxyphenyl)prop-1-en-1-yl]benzene-1,3-diol
-
-
5-[(1E)-2-(4-hydroxyphenyl)prop-1-en-1-yl]benzene-1,3-diol
-
-
5-[(1E)-2-(4-methoxyphenyl)prop-1-en-1-yl]benzene-1,3-diol
-
-
5-[(4-aminobutyl)amino]-1,2-dimethyl-3-[(2,4,6-trifluorophenoxy)methyl]-1H-indole-4,7-dione
-
-
5-[(4-aminobutyl)amino]-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]-1H-indole-4,7-dione
-
-
5-[(8-aminooctyl)amino]-1,2-dimethyl-3-[(2,4,6-trifluorophenoxy)methyl]-1H-indole-4,7-dione
-
-
5-[(Z)-(6-methoxy-2-methylquinolin-4-yl)diazenyl]benzene-1,3-diol
-
-
5-[butyl(methyl)amino]-1,2-dimethyl-3-[(2,4,6-trifluorophenoxy)methyl]-1H-indole-4,7-dione
-
-
5-[[4-(diethylamino)butyl]amino]-10-methoxy-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(diethylamino)butyl]amino]-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(diethylamino)butyl]amino]-7,10-dimethoxy-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(diethylamino)butyl]amino]-7-hydroxy-10-methoxy-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(diethylamino)butyl]amino]-7-hydroxy-8,9-dimethoxy-6H-imidazo[4,5,1-de]acridin-6-one
-
most potent inhibitor of NQO2
5-[[4-(diethylamino)butyl]amino]-8-hydroxy-1-methyl-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(diethylamino)butyl]amino]-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(diethylamino)butyl]amino]-8-methoxy-1-methyl-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(diethylamino)butyl]amino]-8-methoxy-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(diethylamino)butyl]amino]-9-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(dimethylamino)butyl]amino]-1-ethyl-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(dimethylamino)butyl]amino]-1-methyl-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(dimethylamino)butyl]amino]-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(dimethylamino)butyl]amino]-8-hydroxy-1-methyl-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[4-(dimethylamino)butyl]amino]-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[6-(diethylamino)hexyl]amino]-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-[[6-(dimethylamino)hexyl]amino]-6H-imidazo[4,5,1-de]acridin-6-one
-
-
5-{(1E)-1-[4-(dimethylamino)phenyl]but-1-en-2-yl}benzene-1,3-diol
-
-
5-{[2-(dimethylamino)ethyl]amino}-1,2-dimethyl-3-(phenoxymethyl)-1H-indole-4,7-dione
-
-
5-{[2-(dimethylamino)ethyl]amino}-1,2-dimethyl-3-[(2,4,6-trifluorophenoxy)methyl]-1H-indole-4,7-dione
-
-
5-{[2-(dimethylamino)ethyl]amino}-1-methyl-2-phenyl-3-[(2,4,6-trifluorophenoxy)methyl]-1H-indole-4,7-dione
-
-
5-{[2-(dimethylamino)ethyl]amino}-1-methyl-3-[(2,4,6-trifluorophenoxy)methyl]-1H-indole-4,7-dione
-
-
5-{[3-(dimethylamino)propyl]amino}-1,2-dimethyl-3-[(2,4,6-trifluorophenoxy)methyl]-1H-indole-4,7-dione
-
-
6,7,8-trimethoxy-1,4-dimethylquinolin-2(1H)-one
-
-
6,7,8-trimethoxy-4-methylquinolin-2(1H)-one
-
-
6,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one
-
-
6,8-dimethoxy-4-methylquinolin-2(1H)-one
-
-
6,9-dimethyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one
-
-
6-methoxy-2-methyl-4-[(Z)-(4-nitrophenyl)diazenyl]quinoline
-
-
6-methoxy-2-methyl-4-[(Z)-(5-nitrofuran-2-yl)diazenyl]quinoline
-
-
6-methoxy-2-methyl-4-[(Z)-(pyridin-3-yl)diazenyl]quinoline
-
-
6-methoxy-9-methyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one
-
-
6-methyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one
-
-
7,12-dimethylbenz[a]anthracene
-
0.00001 mM, 51% inhibition of the reaction with N1-(n-propyl)-nicotinamide
7,8-dihydroxyflavone
-
0.01 mM, 7% inhibition
7,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one
-
-
7,8-dimethoxy-4-methylquinolin-2(1H)-one
-
-
7-methylbenz[a]anthracene
-
0.00001 mM, 66% inhibition of the reaction with N1-(n-propyl)-nicotinamide
8-bromo-5-[(3-methylbutyl)amino]-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
8-methoxy-1,4-dimethylquinolin-2(1H)-one
-
-
8-methoxy-4-methylquinolin-2(1H)-one
-
-
8-methoxy-5-(phenethylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
-
9,10-dimethylanthracene
-
0.00001 mM, 25% inhibition of the reaction with N1-(n-propyl)-nicotinamide
9-methylanthracene
-
0.00001 mM, 26% inhibition of the reaction with N1-(n-propyl)-nicotinamide
alpha-naphthoflavone
-
0.01 mM, 75% inhibition
benzo[a]pyrene
-
0.0001 mM, 75% inhibition
benz[a]anthracene
-
0.00001 mM, 40% inhibition of the reaction with N1-(n-propyl)-nicotinamide
beta-naphthoflavone
-
0.01 mM, 76% inhibition
chrysin
-
0.01 mM, complete inhibition
chrysin-dimethylether
-
IC50: 0.0013 mM
curcumol
-
curcumol directly targets NQO2 to cause reactive oxygen species generation, which triggers endoplasmic reticulum stress-C/EBP homologous protein death receptor signaling, sensitizing non-small cell lung cancer cells to tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIl) induced apoptosis. Presence of curcumol increases thermal stability of NQO2. Residue Phe178 in NQO2 is a critical site for curcumol binding
-
dabigatran
-
specific binding to the enzyme, protein interaction analysis, overview
dabigatran ethyl ester
-
-
estradiol
-
0.01 mM, 13% inhibition
ethyl 3-(2-((4-(N-(4-(tert-butoxycarbonylamino)butyl)-carbamimidoyl)phenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate
-
-
ethyl N-[(2-{[(4-carbamimidoylphenyl)amino]methyl}-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-b-alaninate
-
-
flavone
-
0.01 mM, 14% inhibition
galangin
-
0.01 mM, complete inhibition
isorhamnetin
-
IC50: 860 nM
kaempferol
-
IC50: 380 nM
methyl 2-((S)-1-cyclohexyl-2-((R)-2-(4-(4-(4-nitrophenylsulfonamido)butylcarbamoyl)benzylcarbamoyl)-azetidin-1-yl)-2-oxoethylamino)acetate
-
-
methyl N-{(1R)-1-cyclohexyl-2-oxo-2-[(2S)-2-{[4-({4-[(N-{17-oxo-21-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]-4,8,12-trioxa-16-azahenicos-1-yl}-N2-{4-[3-(trifluoromethyl)-3H-diaziren-3-yl]benzoyl}-L-alpha-asparaginyl)amino]butyl}carbamoyl)benzyl]carbamoyl}azetidin-1-yl]ethyl}glycinate
-
-
methyl-1-(2-acetamidoethyl)-7-naphthylcarbamate
-
IC50: 0.015 mM
morin
-
0.01 mM, 95% inhibition
N,N'-[methylenedi(4,1-phenylene)]diacetamide
compound is inhibitory, and binding increases the thermal stability of NQO2
-
N-(3,5-dihydroxyphenyl)-4-hydroxybenzamide
-
-
N-acetyl-5-hydroxytryptamine
-
N-[2-(2-iodo-5-methoxy-1-methyl-4-nitroindol-3-yl)ethyl]acetamide
-
inhibits enzymatic mechanism of the enzyme through the MT3 binding site, IC50: 0.0003 mM
N-[2-(2-methoxy-6H-dipyrido[2,3-a:3,2-e]pyrrolizin-11-yl)ethyl]-2-furamide
-
IC50: 14 nM
N-[2-(2-methoxy-6H-pyrido[2',3':4,5]pyrrolo[2,1-a]isoindol-11-yl)ethyl]2-furamide
-
IC50: 0.0002 mM
N-[2-(5-methoxy-4-nitro-1H-indol-3-yl)ethyl]acetamide
-
IC50: 0.0015 mM
N-[2-(5-methoxy-7-nitro-1H-indol-3-yl)ethyl]acetamide
-
IC50: 0.044 mM
N-[2-(7-methylaminosulfonyl-1-naphthyl)ethyl]acetamide
-
IC50: 0.038 mM
N-[2-(8-methoxy-3,4-dihydro-2H-pyrido[2',3':4,5]pyrrolo[2,1-b][1,3]oxazin-10-yl)ethyl]-2-furamide
-
IC50: 0.005 mM
N-{(1R)-1-cyclohexyl-2-oxo-2-[(2S)-2-{[4-({4-[(N-{17-oxo-21-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]-4,8,12-trioxa-16-azahenicos-1-yl}-N2-{4-[3-(trifluoromethyl)-3H-diaziren-3-yl]benzoyl}-L-alpha-asparaginyl)amino]butyl}carbamoyl)benzyl]carbamoyl}azetidin-1-yl]ethyl}glycine
-
-
N-{[1-methyl-2-({[4-(N-{3-[(N-{17-oxo-21-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]-4,8,12-trioxa-16-azahenicos-1-yl}-N2-{4-[3-(trifluoromethyl)-3H-diaziren-3-yl]benzoyl}-L-alpha-asparaginyl)amino]propyl}carbamimidoyl)phenyl]amino}methyl)-1H-benzimidazol-5-yl]carbonyl}-N-pyridin-2-yl-beta-alanine
-
-
N1-[2-(2-methoxy-6H-pyrido[2',3':4,5]pyrrolo[2,1-a]isoindol-11-yl)ethyl]-acetamide
-
IC50: 0.0019 mM
N4-[2-(4-{4-[(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)carbamoyl]benzyl}piperazin-1-yl)ethyl]-N1-{17-oxo-21-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]-4,8,12-trioxa-16-azahenicos-1-yl}-N2-{4-[3-(trifluoromethyl)-3H-diaziren-3-yl]benzoyl}-L-aspartamide
-
-
N4-[3-({N-[(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-phenyl-b-alanyl}amino)propyl]-N1-{17-oxo-21-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]-4,8,12-trioxa-16-azahenicos-1-yl}-N2-{4-[3-(trifluoromethyl)-3H-diaziren-3-yl]benzoyl}-L-aspartamide
-
-
N4-[4-({N-[(1R)-2-{(2R)-2-[(4-carbamimidoylbenzyl)carbamoyl]cyclobutyl}-1-cyclohexylprop-2-en-1-yl]glycyl}amino)butyl]-N1-{17-oxo-21-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]-4,8,12-trioxa-16-azahenicos-1-yl}-N2-{4-[3-(trifluoromethyl)-3H-diaziren-3-yl]benzoyl}-L-aspartamide
-
-
NSC106080
-
i.e. bis(2-hydroxyphenyl)methanone phenylhydrazone
NSC115890
-
i.e. 1,3-naphthalenediol
NSC180969
-
i.e. 7,8-dimethoxy-4-(3,4,5-trimethoxyphenyl)-1,2-dihydro-3H-benzo[e]isoindol-3-one
NSC187208
-
i.e. N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine, chloroquine
NSC204996
-
i.e. 7,8-dimethoxy-4-(3,4,5-trimethoxyphenyl)-2,3-dihydro-1H-benzo[e]isoindole
NSC238146
-
i.e. N4-(6-((6-amino-2-methyl-4-quinolinyl)amino)hexyl)-2-methyl-4,6-quinolinediamine acetate
NSC27296
-
i.e. N4-(6-methoxy-8-quinolinyl)-1,4-pentanediamine, primaquine
NSC300853
-
i.e. 3-amino-9-ethyl-2-((4-(hydroxy(oxido)amino)phenyl)diazenyl)-9H-carbazole
NSC306843
-
i.e. 1-methyl-4(1H)-quinolinone (1-methyl-4(1H)-quinolinylidene)hydrazone
NSC332172
-
i.e. 2-(4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)acrylonitrile
NSC356819
-
i.e. 4-((2-hydroxy-5-(phenyldiazenyl)phenyl)diazenyl)benzenecarboximidamide
NSC356820
-
i.e. 4-((2-hydroxy-5-(2-phenylvinyl)phenyl)diazenyl)benzenecarboximidamide
NSC359466
-
i.e. 4-((4-(amino(imino)methyl)phenyl)diazenyl)-3-hydroxy-N-phenyl-2-naphthamide
NSC381864
-
i.e. 5-(2-(3,5-dimethoxyphenyl)vinyl)-2-methoxyphenol
NSC621351
-
i.e. 2-(2-fluorophenyl)-4-(2-naphthyl)-2,3-dihydro-1,5-benzothiazepine
NSC623234
-
i.e. 3-chloro-3-(3,4-dimethoxyphenyl)-2-(3,4,5-trimethoxyphenyl)acrylaldehyde
NSC640353
-
i.e. 1-(2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl)-4-methyl-5-phenyl-2,4-pentadien-1-one
NSC640556
-
i.e. 1-(2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl)-3-(4-(hydroxy(oxido)amino)phenyl)-2-propen-1-one
NSC640558
-
i.e 1-(2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl)-3-phenyl-2-propen-1-one
NSC640559
-
i.e. 1-(2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl)-3-(3-(hydroxy(oxido)amino)phenyl)-2-propen-1-one
NSC640566
-
i.e. 3-(4-chlorophenyl)-1-(2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl)-2-propen-1-one
NSC640583
-
i.e. 1-(2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl)-3-(4-methylphenyl)-2-propen-1-one
NSC640584
-
i.e. 3-(3,4-dichlorophenyl)-1-(2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl)-2-propen-1-one
NSC648420
-
i.e. 1,2,3-trimethoxyphenanthro[2,3-d][1,3]dioxol-6-yl acetate
NSC648422
-
i.e. 5-(1-methyl-2-(3,4,5-trimethoxyphenyl)vinyl)-1,3-benzodioxole
NSC649091
-
i.e. 2-((diethylamino)methyl)-4-((10-methyl-10H-indolo[3,2-b]quinolin-11-yl)amino)phenol hydrochloride
NSC65069
-
i.e. [1,1'-biphenyl]-2,3',4,5',6-pentol
NSC66167
-
i.e. [1,1'-biphenyl]-2,2',4,4'-tetrol
NSC665126
-
i.e. 1-(2-(4-(hydroxy(oxido)amino)phenyl)vinyl)-3-phenylbenzo[f]quinoline
NSC669977
-
i.e. 6-imino-1-methyl-3-phenyl-2,6-dihydro-5(1H)-quinolinone hydrazone
NSC676468
-
i.e. N-(3-([1,10-biphenyl]-4-ylimino)-1-propenyl)[1,10-biphenyl]-4-amine
NSC677939
-
i.e. 14H-diindolo[2,3-a:3,2-h]quinolizine
NSC693571
-
i.e. trifluoromethanesulfonic acid compound with N,N-dimethyl-4-((1-methyl-2-phenyl-4H-1lambda5-pyrazolo[1,5-a]indol-4-ylidene)methyl)aniline
NSC720622
-
i.e. trifluoromethanesulfonic acid compound with N,N-dimethyl-4-((1-methyl-6-nitro-2-phenylpyrazolo[1,5-a]indol-1-ium-4-ylidene)methyl)aniline
NSC77833
-
i.e. 1-(2-(1H-indol-3-yl)vinyl)isoquinoline
NSC78017
-
i.e. 2,6-dimethyl-3H-pyrrolo[3,2-f]quinoline
NSC78021
-
i.e. 4,7-dimethyl-7H-pyrido[2,3-c]carbazole
NSC86715
-
i.e. 5-methyl-1-phenyl-6H-pyrido[4,3-b]carbazole
NSC97374
-
i.e. 1-ethyl-2-((1-ethyl-2(1H)-quinolinylidene)methyl)-1lambda5-quinoline
NSC99495
-
i.e. 3-benzo[a]anthracen-12-ylthiophene
NSC99528
-
i.e. 2-benzo[a]anthracen-12-yl-1-benzothiophene
quercetin-3-O-beta-glucopyranosyl
-
IC50: 0.0015 mM
S28128
-
IC50: 0.00091 mM
tert-butyl (S)-1-cyclohexyl-2-((R)-2-(4-(4-(4-nitrophenylsulfonamido)butylcarbamoyl)benzylcarbamoyl)-azetidin-1-yl)-2-oxoethylcarbamate
-
-
tert-butyl 4-(4-(4-nitrophenylsulfonamido)butylcarbamoyl)-benzylcarbamate
-
-
2-iodomelatonin
-
-
5-methoxycarbonylamino-N-acetyltryptamine
-
-
5-methoxycarbonylamino-N-acetyltryptamine
-
-
apigenin
-
IC50: 430 nM
benzo(a)pyrene
-
-
benzo(a)pyrene
20 mM, 90% inhibition
Chloroquine
-
-
Chloroquine
binds preferentially to reduced NQO2, binding mode, closure of a flexible loop (Phe126-Leu136) over the active site, overview
chrysoeriol
-
IC50: 300 nM
dicoumarol
-
0.01 mM, 25% inhibition
dicoumarol
-
IC50: 0.59 mM
dicoumarol
-
0.01 mM, marginal inhibition
imatinib
the structure of the imatinib-NQO2 complex demonstrates that imatinib inhibits NQO2 activity by competing with substrate for the active site
luteolin
-
IC50: 780 nM
Melatonin
-
IC50: 0.13 mM
Melatonin
competitive inhibitor against N-methyldihydronicotinamide, uncompetitive against menadione. Melatonin and its analogues bind to and inhibit QR2 within the active site and not at an allosteric site
Melatonin
-
QR2 is inhibited in the micromolar range by melatonin, but not when using N-benzyl dihydronicotinamide and coenzyme Q2 are used as substrates
N-acetylserotonin
-
IC50: 0.099 mM
NSC660841
-
most potent inhibitor of NQO2
NSC660841
-
one of the most potent inhibitors of NQO2
primaquine
-
-
primaquine
binding mode, overview
quercetin
-
0.01 mM, complete inhibition
quercetin
-
IC50: 0.0014 mM
resveratrol
the chemopreventive and cardioprotective properties of resveratrol are possibly the results of QR2 activity inhibition, which in turn, up-regulates the expression of cellular antioxidant enzymes and cellular resistance to oxidative stress. All three resveratrol hydroxyl groups form hydrogen bonds with amino acids from QR2, anchoring a flat resveratrol molecule in parallel with the isoalloxazine ring of FAD
resveratrol
-
i.e. 3,5,4'-trihydroxylstilbene, resveratrol binds tightly to the oxidized, FAD-form of the enzyme, and it acts as a competitive inhibitor against N-methyldihydronicotinamide. The amount of resveratrol consumed from dietary sources may be sufficient for effective inhibition of QR2
S26553
-
-
S26553
-
i.e. N-methyl-[1-[2-(acetylamino)ethyl]naphthalen-7-yl]-carbamate
S26695
-
i.e. N-[2-(7-methylaminosulfonyl-1-naphthyl)ethyl]acetamide
S26695
-
selective inhibitor of QR2
S29434
-
i.e. N-[2-(2-methoxy-6H-dipyrido[2,3-a:3,2-e]pyrrolizin-11-yl)ethyl]-2-furamide, inhibits QR2 activity with an IC50 in the low nanomolar range from 0.7 to 80 nM, depending on the substrates and co-substrates used
S29434
-
synthetic compound, complete inhibition
S29434
-
selective inhibitor of QR2
additional information
-
melatonin has no effect
-
additional information
-
no inhibition by 4-methylquinolin-2(1H)-one. 6-Methoxy-9-methyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one and its analogues merit further investigation as potential chemopreventive or chemotherapeutic agents
-
additional information
-
dicoumarol is inactive up to 0.1 mM
-
additional information
-
enzyme inhibitor design, synthesiis, and evaluation, inhibitory potencies of resveratrol analogues, overview. Inhibitor binding structure, modelling, overview
-
additional information
-
development of potent and selective mechanism-based inhibitors centered on the indolequinone pharmacophore. The compounds show remarkable selectivity for NQO2 over the closely related flavoprotein NQO1, with small structural changes defining selectivity, detailed overview. The inhibitor's mode of action involving alkylation of the flavin cofactor, provides significant advantages over existing competitive inhibitors in terms of potency and irreversibility
-
additional information
-
inhibitor binding structures, overview
-
additional information
-
molecular dockings predicts and biological experiments confirm that dabigatran ethyl ester inhibits NQO2 even more effectively than the parent compound itself, usage of capture compounds, overview
-
additional information
study on 4-aminoquinoline hydrazone inhibitors. A small substituent at the 2-position of the 4-aminoquinoline ring is important to reduce steric hindrance and improve engagement of the scaffold within the NQO2 active site. Both the hydrazone and hydrazide derivatives are functionally active as inhibitors of NQO2 in the cells
-
additional information
not inhibited by dicoumarol, Cibacron blue, phenindone
-
additional information
-
not inhibited by dicoumarol, Cibacron blue, phenindone
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0182
1,4-dimethylquinolin-2(1H)-one
Homo sapiens
-
23°C
0.00087
2-(2-methoxy-6H-pyrido[2',3':4,5]pyrrolo[2,1-a]isoindol-11-yl)ethylamine
Homo sapiens
-
IC50: 0.00087 mM
0.016
2-iodo-melatonin
Homo sapiens
-
IC50: 0.016 mM
0.0011
2-iodomelatonin
Homo sapiens
pH 8, 25°C
0.013
2-methoxy-6-((2-(6-methoxy-2-methylquinolin-4-yl)hydrazono)methyl)phenol
Homo sapiens
pH 7.4, 37°C
-
0.125 - 0.137
3-[(Z)-(6-methoxy-2-methylquinolin-4-yl)diazenyl]phenol
-
0.000068
4-(5-phenylfuran-2-yl)benzene-1-carboximidamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
-
0.00077
4-(5-phenylthiophen-2-yl)benzene-1-carboximidamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
-
0.071
4-[(Z)-(1H-imidazol-4-yl)diazenyl]-6-methoxy-2-methylquinoline
Homo sapiens
pH 7.4, 37°C
-
0.103
4-[(Z)-(4-fluorophenyl)diazenyl]-6-methoxy-2-methylquinoline
Homo sapiens
pH 7.4, 37°C
-
0.064
4-[(Z)-(6-methoxy-2-methylquinolin-4-yl)diazenyl]benzoic acid
Homo sapiens
pH 7.4, 37°C
-
0.055
4-[(Z)-(6-methoxy-2-methylquinolin-4-yl)diazenyl]phenol
Homo sapiens
pH 7.4, 37°C
-
0.015
4-[(Z)-benzyldiazenyl]-6-methoxy-2-methylquinoline
Homo sapiens
pH 7.4, 37°C
-
0.09
4-[(Z)-[(1H-imidazol-4-yl)methyl]diazenyl]-6-methoxy-2-methylquinoline
Homo sapiens
pH 7.4, 37°C
-
0.0108
5,6,8-trimethoxy-1,4-dimethylquinolin-2(1H)-one
Homo sapiens
-
23°C
0.006
5,6,8-trimethoxy-4-methylquinolin-2(1H)-one
Homo sapiens
-
23°C
0.0041
5,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one
Homo sapiens
-
23°C
0.0108
5,8-dimethoxy-4-methylquinolin-2(1H)-one
Homo sapiens
-
23°C
0.001833
5-(2-(dimethylamino)ethylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
Homo sapiens
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.000167
5-(2-(dimethylamino)ethylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one N-oxide
Homo sapiens
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.001483
5-(2-(dimethylamino)ethylamino)-8-bromo-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
Homo sapiens
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.000117
5-(2-(dimethylamino)ethylamino)-8-bromo-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one N-oxide
Homo sapiens
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.000783
5-(2-(dimethylamino)ethylamino)-8-fluoro-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
Homo sapiens
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.001333
5-(2-(dimethylamino)ethylamino)-8-methoxy-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
Homo sapiens
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.000098
5-(2-(dimethylamino)ethylamino)-8-methoxy-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one N-oxide
Homo sapiens
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.000483
5-(3-hydroxypropylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
Homo sapiens
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.000987
5-(3-hydroxypropylamino)-8-bromo-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
Homo sapiens
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.000517
5-(3-hydroxypropylamino)-8-methoxy-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
Homo sapiens
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.000098
5-(4-methoxyphenylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
Homo sapiens
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.000427
5-(isopentylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
Homo sapiens
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.000567
5-(phenethylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
Homo sapiens
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.00034
5-hydroxyflavone
Homo sapiens
-
IC50: 340 nM
0.0539
5-hydroxytryptamine
Homo sapiens
pH 8, 25°C
0.295
5-methoxy-carbonylamino-N-acetyltryptamine
Homo sapiens
-
IC50: 0.295 mM
0.046
5-[(Z)-(6-methoxy-2-methylquinolin-4-yl)diazenyl]benzene-1,3-diol
Homo sapiens
pH 7.4, 37°C
-
0.000099
5-[[4-(diethylamino)butyl]amino]-10-methoxy-6H-imidazo[4,5,1-de]acridin-6-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000427
5-[[4-(diethylamino)butyl]amino]-6H-imidazo[4,5,1-de]acridin-6-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000017
5-[[4-(diethylamino)butyl]amino]-7,10-dimethoxy-6H-imidazo[4,5,1-de]acridin-6-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000031
5-[[4-(diethylamino)butyl]amino]-7-hydroxy-10-methoxy-6H-imidazo[4,5,1-de]acridin-6-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000006
5-[[4-(diethylamino)butyl]amino]-7-hydroxy-8,9-dimethoxy-6H-imidazo[4,5,1-de]acridin-6-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000016
5-[[4-(diethylamino)butyl]amino]-8-hydroxy-1-methyl-6H-imidazo[4,5,1-de]acridin-6-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000148
5-[[4-(diethylamino)butyl]amino]-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000009
5-[[4-(diethylamino)butyl]amino]-8-methoxy-1-methyl-6H-imidazo[4,5,1-de]acridin-6-one
Homo sapiens
-
pH and temperature not specified in the publication
0.001
5-[[4-(diethylamino)butyl]amino]-8-methoxy-6H-imidazo[4,5,1-de]acridin-6-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000953
5-[[4-(diethylamino)butyl]amino]-9-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000693
5-[[4-(dimethylamino)butyl]amino]-1-ethyl-6H-imidazo[4,5,1-de]acridin-6-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000323
5-[[4-(dimethylamino)butyl]amino]-1-methyl-6H-imidazo[4,5,1-de]acridin-6-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00083
5-[[4-(dimethylamino)butyl]amino]-6H-imidazo[4,5,1-de]acridin-6-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00005
5-[[4-(dimethylamino)butyl]amino]-8-hydroxy-1-methyl-6H-imidazo[4,5,1-de]acridin-6-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000296
5-[[4-(dimethylamino)butyl]amino]-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000597
5-[[6-(diethylamino)hexyl]amino]-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one
Homo sapiens
-
pH and temperature not specified in the publication
0.000172
5-[[6-(dimethylamino)hexyl]amino]-6H-imidazo[4,5,1-de]acridin-6-one
Homo sapiens
-
pH and temperature not specified in the publication
0.007
6,7,8-trimethoxy-1,4-dimethylquinolin-2(1H)-one
Homo sapiens
-
23°C
0.01
6,7,8-trimethoxy-4-methylquinolin-2(1H)-one
Homo sapiens
-
23°C
0.0019
6,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one
Homo sapiens
-
23°C
0.0088
6,8-dimethoxy-4-methylquinolin-2(1H)-one
Homo sapiens
-
23°C
0.0062
6,9-dimethyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one
Homo sapiens
-
23°C
0.083
6-methoxy-2-methyl-4-[(Z)-(4-nitrophenyl)diazenyl]quinoline
Homo sapiens
pH 7.4, 37°C
-
0.018
6-methoxy-2-methyl-4-[(Z)-(5-nitrofuran-2-yl)diazenyl]quinoline
Homo sapiens
pH 7.4, 37°C
-
0.01
6-methoxy-2-methyl-4-[(Z)-(pyridin-3-yl)diazenyl]quinoline
Homo sapiens
pH 7.4, 37°C
-
0.0541
6-methoxy-9-methyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one
Homo sapiens
-
23°C
0.0108
6-methyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one
Homo sapiens
-
23°C
0.0093
7,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one
Homo sapiens
-
23°C
0.0293
7,8-dimethoxy-4-methylquinolin-2(1H)-one
Homo sapiens
-
23°C
0.000767
8-bromo-5-[(3-methylbutyl)amino]-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
Homo sapiens
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0058
8-methoxy-1,4-dimethylquinolin-2(1H)-one
Homo sapiens
-
23°C
0.0241
8-methoxy-4-methylquinolin-2(1H)-one
Homo sapiens
-
23°C
0.00035
8-methoxy-5-(phenethylamino)-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one
Homo sapiens
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.00028 - 0.00043
apigenin
0.0013
chrysin-dimethylether
Homo sapiens
-
IC50: 0.0013 mM
0.000016 - 0.00082
chrysoeriol
0.06
dabigatran
Homo sapiens
-
pH and temperature not specified in the publication
0.0008
dabigatran ethyl ester
Homo sapiens
-
pH and temperature not specified in the publication
0.59
dicoumarol
Homo sapiens
-
IC50: 0.59 mM
0.0074
diosmetin
Homo sapiens
pH 8.5, 25°C
0.081
eridictylol
Homo sapiens
pH 8.5, 25°C
-
0.07
hesperetin
Homo sapiens
pH 8.5, 25°C
0.00086
isorhamnetin
Homo sapiens
-
IC50: 860 nM
0.00038
kaempferol
Homo sapiens
-
IC50: 380 nM
0.00015 - 0.00078
luteolin
0.015
methyl-1-(2-acetamidoethyl)-7-naphthylcarbamate
Homo sapiens
-
IC50: 0.015 mM
0.0099
N-acetyl-5-hydroxytryptamine
Homo sapiens
pH 8, 25°C
0.099
N-acetylserotonin
Homo sapiens
-
IC50: 0.099 mM
0.0003
N-[2-(2-iodo-5-methoxy-1-methyl-4-nitroindol-3-yl)ethyl]acetamide
Homo sapiens
-
inhibits enzymatic mechanism of the enzyme through the MT3 binding site, IC50: 0.0003 mM
0.000014
N-[2-(2-methoxy-6H-dipyrido[2,3-a:3,2-e]pyrrolizin-11-yl)ethyl]-2-furamide
Homo sapiens
-
IC50: 14 nM
0.0002
N-[2-(2-methoxy-6H-pyrido[2',3':4,5]pyrrolo[2,1-a]isoindol-11-yl)ethyl]2-furamide
Homo sapiens
-
IC50: 0.0002 mM
0.0015
N-[2-(5-methoxy-4-nitro-1H-indol-3-yl)ethyl]acetamide
Homo sapiens
-
IC50: 0.0015 mM
0.044
N-[2-(5-methoxy-7-nitro-1H-indol-3-yl)ethyl]acetamide
Homo sapiens
-
IC50: 0.044 mM
0.038
N-[2-(7-methylaminosulfonyl-1-naphthyl)ethyl]acetamide
Homo sapiens
-
IC50: 0.038 mM
0.005
N-[2-(8-methoxy-3,4-dihydro-2H-pyrido[2',3':4,5]pyrrolo[2,1-b][1,3]oxazin-10-yl)ethyl]-2-furamide
Homo sapiens
-
IC50: 0.005 mM
0.0019
N1-[2-(2-methoxy-6H-pyrido[2',3':4,5]pyrrolo[2,1-a]isoindol-11-yl)ethyl]-acetamide
Homo sapiens
-
IC50: 0.0019 mM
0.049
naringenin
Homo sapiens
pH 8.5, 25°C
0.0039
NSC106080
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0033
NSC115890
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.002
NSC180969
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0015
NSC187208
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0027
NSC204996
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0019
NSC238146
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0075
NSC27296
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.005
NSC300853
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0062
NSC306843
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.02
NSC332172
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0018
NSC356819
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0014
NSC356820
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.006
NSC359466
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.015
NSC381864
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.022
NSC623234
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.00005
NSC637991
Homo sapiens
-
pH and temperature not specified in the publication
0.000016
NSC637992
Homo sapiens
-
pH and temperature not specified in the publication
0.000009
NSC637993
Homo sapiens
-
pH and temperature not specified in the publication
0.000597
NSC637994
Homo sapiens
-
pH and temperature not specified in the publication
0.0038
NSC640353
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.006
NSC640556
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0058
NSC640558
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0065
NSC640559
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0053
NSC640566
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0032
NSC640583
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0049
NSC640584
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.000296
NSC645808
Homo sapiens
-
pH and temperature not specified in the publication
0.000148
NSC645809
Homo sapiens
-
pH and temperature not specified in the publication
0.000953
NSC645811
Homo sapiens
-
pH and temperature not specified in the publication
0.001
NSC645812
Homo sapiens
-
pH and temperature not specified in the publication
0.000427
NSC645831
Homo sapiens
-
pH and temperature not specified in the publication
0.00083
NSC645833
Homo sapiens
-
pH and temperature not specified in the publication
0.000323
NSC645834
Homo sapiens
-
pH and temperature not specified in the publication
0.000693
NSC645835
Homo sapiens
-
pH and temperature not specified in the publication
0.000172
NSC645836
Homo sapiens
-
pH and temperature not specified in the publication
0.0035
NSC649091
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.000099
NSC660838
Homo sapiens
-
pH and temperature not specified in the publication
0.000017
NSC660839
Homo sapiens
-
pH and temperature not specified in the publication
0.000031
NSC660840
Homo sapiens
-
pH and temperature not specified in the publication
0.000006
NSC660841
Homo sapiens
-
pH and temperature not specified in the publication
0.0058
NSC66167
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0096
NSC665126
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.002
NSC669977
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0097
NSC676468
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0029
NSC677939
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0017
NSC693571
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.005
NSC720622
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0018
NSC77833
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0021
NSC78017
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0055
NSC78021
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0021
NSC86715
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0027
NSC97374
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.0051
NSC99495
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.006
NSC99528
Homo sapiens
-
in 50 mM phosphate buffer at pH 7.4, at 37°C
0.00053 - 0.0014
quercetin
0.0015
quercetin-3-O-beta-glucopyranosyl
Homo sapiens
-
IC50: 0.0015 mM
0.000129 - 0.07
resveratrol
0.00091
S28128
Homo sapiens
-
IC50: 0.00091 mM
0.0000007 - 0.000079
S29434
0.125
3-[(Z)-(6-methoxy-2-methylquinolin-4-yl)diazenyl]phenol
Homo sapiens
pH 7.4, 37°C
-
0.137
3-[(Z)-(6-methoxy-2-methylquinolin-4-yl)diazenyl]phenol
Homo sapiens
pH 7.4, 37°C
-
0.00028
apigenin
Homo sapiens
pH 8.5, 25°C
0.00043
apigenin
Homo sapiens
-
IC50: 430 nM
0.000016
chrysoeriol
Homo sapiens
-
using nicotinamide riboside and menadione as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.000076
chrysoeriol
Homo sapiens
-
using nicotinamide riboside and coenzyme Q2 as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.00016
chrysoeriol
Homo sapiens
-
using N-benzyl dihydronicotinamide and menadione as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.0003
chrysoeriol
Homo sapiens
-
IC50: 300 nM
0.00082
chrysoeriol
Homo sapiens
-
using N-benzyl dihydronicotinamide and coenzyme Q2 as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.00015
luteolin
Homo sapiens
pH 8.5, 25°C
0.00078
luteolin
Homo sapiens
-
IC50: 780 nM
0.0028
Melatonin
Homo sapiens
-
using nicotinamide riboside and menadione as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.0113
Melatonin
Homo sapiens
-
23°C
0.0113
Melatonin
Homo sapiens
pH 8, 25°C
0.0397
Melatonin
Homo sapiens
-
using nicotinamide riboside and coenzyme Q2 as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.0415
Melatonin
Homo sapiens
-
using N-benzyl dihydronicotinamide and menadione as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.13
Melatonin
Homo sapiens
-
IC50: 0.13 mM
0.00053
quercetin
Homo sapiens
pH 8.5, 25°C
0.0014
quercetin
Homo sapiens
-
IC50: 0.0014 mM
0.000129
resveratrol
Homo sapiens
-
using nicotinamide riboside and menadione as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.000143
resveratrol
Homo sapiens
-
using N-benzyl dihydronicotinamide and menadione as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.00096
resveratrol
Homo sapiens
-
23°C
0.00096
resveratrol
Homo sapiens
pH 8, 25°C
0.0029
resveratrol
Homo sapiens
-
using nicotinamide riboside and coenzyme Q2 as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.07
resveratrol
Homo sapiens
-
using N-benzyl dihydronicotinamide and coenzyme Q2 as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.0012
S26695
Homo sapiens
-
using nicotinamide riboside and menadione as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.0025
S26695
Homo sapiens
-
using N-benzyl dihydronicotinamide and coenzyme Q2 as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.0126
S26695
Homo sapiens
-
using nicotinamide riboside and coenzyme Q2 as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.0151
S26695
Homo sapiens
-
using N-benzyl dihydronicotinamide and menadione as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.0000007
S29434
Homo sapiens
-
using nicotinamide riboside and menadione as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.000005
S29434
Homo sapiens
-
using nicotinamide riboside and coenzyme Q2 as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.0000067
S29434
Homo sapiens
-
using N-benzyl dihydronicotinamide and menadione as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
0.000079
S29434
Homo sapiens
-
using N-benzyl dihydronicotinamide and coenzyme Q2 as substrates, at 25°C, in 50 mM Tris-HCl, pH 8.5
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Wu, K.; Knox, R.; Sun, X.Z.; Joseph, P.; Jaiswal, A.K.; Zhang, D.; Deng, P.S.K.; Chen, S.
Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase
Arch. Biochem. Biophys.
347
221-228
1997
Homo sapiens
brenda
Vella, F.; Ferry, G.; Delagrange, P.; Boutin, J.A.
NRH:quinone reductase 2: an enzyme of surprises and mysteries
Biochem. Pharmacol.
71
1-12
2005
Mus musculus, Homo sapiens (P16083)
brenda
Mailliet, F.; Ferry, G.; Vella, F.; Berger, S.; Coge, F.; et.al.
Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme
Biochem. Pharmacol.
71
74-88
2005
Homo sapiens
brenda
Buryanovskyy, L.; Fu, Y.; Boyd, M.; Ma, Y.; Hsieh, T.; Wu, J.M.; Zhang, Z.
Crystal structure of quinone reductase 2 in complex with resveratrol
Biochemistry
43
11417-11426
2004
Homo sapiens (P16083)
brenda
Long, D.J.2nd.; Jaiswal, A.K.
NRH:quinone oxidoreductase2 (NQO2)
Chem. Biol. Interact.
129
99-112
2000
Homo sapiens
brenda
Boutin, J.A.; Chatelein-Egger, F.; Vella, F.; Delagrange, P.; Ferry, G.
Quinone reductase 2 substrate specificity and inhibitgion pharmacology
Chem. Biol. Interact.
151
213-228
2005
Homo sapiens
brenda
Mailliet, F.; Ferry, G.; Vella, F.; Thiam, K.; Delagrange, P.; Boutin, J.A.
Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3
FEBS Lett.
578
116-120
2004
Mus musculus
brenda
Long, D.J.; Jaiswal, A.K.
Mouse NRH:quinone oxidoreductase (NQO2): cloning of cDNA and gene- and tissue-specific expression
Gene
252
107-117
2000
Mus musculus (Q9JI75), Mus musculus
brenda
Liao, S.; Dulaney, J.T.; Williams-Ashman, H-.G.
Purification and properties of a flavoprotein catalyzing the oxidation of reduced ribosyl nicotinamide
J. Biol. Chem.
237
2981-2987
1962
Bos taurus, Rattus norvegicus
brenda
Nosjean, O.; Ferro, M.; Coge, F.; Beauverger, P.; et al.
Identification of the melatonin-binding site MT3 as the quinone reductase 2
J. Biol. Chem.
275
31311-31317
2000
Homo sapiens, Mesocricetus auratus
brenda
Strassburg, A.; Strassburg, C.P.; Manns, M.P.; Tukey, R.H.
Differential gene expression of NAD(P)H:quinone oxidoreductase and NRH:quinone oxidoreductase in human hepatocellular and biliary tissue
Mol. Pharmacol.
61
320-325
2002
Homo sapiens (P16083), Homo sapiens
brenda
Graves, P.R.; Kwiek, J.J.; Fadden, P.; et al.
Discovery of novel targets of quinoline drugs in the human purine binding proteome
Mol. Pharmacol.
62
1364-1372
2002
Homo sapiens
brenda
Zhao, Q.; Yang, X.L.; Holtzclaw, W.D.; Talalay, P.
Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase)
Proc. Natl. Acad. Sci. USA
94
1669-1674
1997
Bos taurus, Homo sapiens
brenda
Fu, Y.; Buryanovskyy, L.; Zhang, Z.
Crystal structure of quinone reductase 2 in complex with cancer prodrug CB1954
Biochem. Biophys. Res. Commun.
336
332-338
2005
Homo sapiens
brenda
Celli, C.M.; Tran, N.; Knox, R.; Jaiswal, A.K.
NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs
Biochem. Pharmacol.
72
366-376
2006
Mus musculus (Q9JI75), Mus musculus
brenda
Wang, W.; Jaiswal, A.K.
Nulear factor Nrf2 and antioxidant response element regulate NRH:quinone oxidoreductase 2 (NQO2) gene expression and antioxidant induction
Free Radic. Biol. Med.
40
1119-1130
2006
Homo sapiens
brenda
Iskander, K.; Li, J.; Han, S.; Zheng, B.; Jaiswal, A.K.
NQO1 and NQO2 regulation of humoral immunity and autoimmunity
J. Biol. Chem.
281
30917-30924
2006
Mus musculus
brenda
Okada, S.; Farin, F.M.; Stapleton, P.; Viernes, H.; Quigley, S.D.; Powers, K.M.; Smith-Weller, T.; Franklin, G.M.; Longstreth, W.T.; Swanson, P.D.; Checkoway, H.
No associations between Parkinsons disease and polymorphisms of the quinone oxidoreductase (NQO1, NQO2) genes
Neurosci. Lett.
375
178-180
2005
Homo sapiens
brenda
Jamieson, D.; Wilson, K.; Pridgeon, S.; Margetts, J.P.; Edmondson, R.J.; Leung, H.Y.; Knox, R.; Boddy, A.V.
NAD(P)H:quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism
Clin. Cancer Res.
13
1584-1590
2007
Homo sapiens
brenda
Wang, W.; Le, W.; Pan, T.; Stringer, J.L.; Jaiswal, A.K.
Association of NRH:quinone oxidoreductase 2 gene promoter polymorphism with higher gene expression and increased susceptibility to Parkinsons disease
J. Gerontol. A Biol. Sci. Med. Sci.
63
127-134
2008
Homo sapiens
brenda
Boutin, J.A.; Saunier, C.; Guenin, S.P.; Berger, S.; Moulharat, N.; Gohier, A.; Delagrange, P.; Coge, F.; Ferry, G.
Studies of the melatonin binding site location onto quinone reductase 2 by directed mutagenesis
Arch. Biochem. Biophys.
477
12-19
2008
Homo sapiens
brenda
Calamini, B.; Santarsiero, B.D.; Boutin, J.A.; Mesecar, A.D.
Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2
Biochem. J.
413
81-91
2008
Homo sapiens (P16083)
brenda
Winger, J.A.; Hantschel, O.; Superti-Furga, G.; Kuriyan, J.
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)
BMC Struct. Biol.
9
7
2009
Homo sapiens (P16083), Homo sapiens
brenda
Cai, J.B.; Zhang, Z.H.; Xu, D.J.; Qian, Z.Y.; Wang, Z.R.; Huang, Y.Z.; Zou, J.G.; Cao, K.J.
Negative regulation of quinone reductase 2 by resveratrol in cultured vascular smooth muscle cells
Clin. Exp. Pharmacol. Physiol.
35
1419-1425
2008
Oryctolagus cuniculus
brenda
Gaikwad, N.W.; Yang, L.; Rogan, E.G.; Cavalieri, E.L.
Evidence for NQO2-mediated reduction of the carcinogenic estrogen ortho-quinones
Free Radic. Biol. Med.
46
253-262
2009
Homo sapiens
brenda
Fu, Y.; Buryanovskyy, L.; Zhang, Z.
Quinone reductase 2 is a catechol quinone reductase
J. Biol. Chem.
283
23829-23835
2008
Rattus norvegicus
brenda
Maiti, A.; Reddy, P.V.; Sturdy, M.; Marler, L.; Pegan, S.D.; Mesecar, A.D.; Pezzuto, J.M.; Cushman, M.
Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities
J. Med. Chem.
52
1873-1884
2009
Homo sapiens
brenda
Nolan, K.A.; Humphries, M.P.; Bryce, R.A.; Stratford, I.J.
Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2
Bioorg. Med. Chem. Lett.
20
2832-2836
2010
Homo sapiens
brenda
Nolan, K.A.; Caraher, M.C.; Humphries, M.P.; Bettley, H.A.; Bryce, R.A.; Stratford, I.J.
In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2)
Bioorg. Med. Chem. Lett.
20
7331-7336
2010
Homo sapiens
brenda
Nolan, K.A.; Humphries, M.P.; Barnes, J.; Doncaster, J.R.; Caraher, M.C.; Tirelli, N.; Bryce, R.A.; Whitehead, R.C.; Stratford, I.J.
Triazoloacridin-6-ones as novel inhibitors of the quinone oxidoreductases NQO1 and NQO2
Bioorg. Med. Chem.
18
696-706
2010
Homo sapiens (P16083)
brenda
Ferry, G.; Hecht, S.; Berger, S.; Moulharat, N.; Coge, F.; Guillaumet, G.; Leclerc, V.; Yous, S.; Delagrange, P.; Boutin, J.A.
Old and new inhibitors of quinone reductase 2
Chem. Biol. Interact.
186
103-109
2010
Homo sapiens
brenda
Benoit, C.E.; Bastianetto, S.; Brouillette, J.; Tse, Y.; Boutin, J.A.; Delagrange, P.; Wong, T.; Sarret, P.; Quirion, R.
Loss of quinone reductase 2 function selectively facilitates learning behaviors
J. Neurosci.
30
12690-12700
2010
Rattus norvegicus
brenda
John, S.E.St.; Jensen, K.C.; Kang, S.; Chen, Y.; Calamini, B.; Mesecar, A.D.; Lipton, M.A.
Design, synthesis, biological and structural evaluation of functionalized resveratrol analogues as inhibitors of quinone reductase 2
Bioorg. Med. Chem.
21
6022-6037
2013
Homo sapiens
brenda
Dufour, M.; Yan, C.; Siegel, D.; Colucci, M.A.; Jenner, M.; Oldham, N.J.; Gomez, J.; Reigan, P.; Li, Y.; De Matteis, C.I.; Ross, D.; Moody, C.J.
Mechanism-based inhibition of quinone reductase 2 (NQO2): selectivity for NQO2 over NQO1 and structural basis for flavoprotein inhibition
ChemBioChem
12
1203-1208
2011
Homo sapiens
brenda
Reybier, K.; Perio, P.; Ferry, G.; Bouajila, J.; Delagrange, P.; Boutin, J.A.; Nepveu, F.
Insights into the redox cycle of human quinone reductase 2
Free Radic. Res.
45
1184-1195
2011
Homo sapiens
brenda
Antoine, M.; Marcheteau, E.; Delagrange, P.; Ferry, G.; Boutin, J.
Characterization of cofactors, substrates and inhibitor binding to flavoenzyme quinone reductase 2 by automated supramolecular nano-electrospray ionization mass spectrometry
Int. J. Mass Spectrom.
312
87-96
2012
Homo sapiens
-
brenda
Leung, K.K.; Shilton, B.H.
Chloroquine binding reveals flavin redox switch function of quinone reductase 2
J. Biol. Chem.
288
11242-11251
2013
Homo sapiens (P16083), Homo sapiens
brenda
Michaelis, S.; Marais, A.; Schrey, A.K.; Graebner, O.Y.; Schaudt, C.; Sefkow, M.; Kroll, F.; Dreger, M.; Glinski, M.; Koester, H.; Metternich, R.; Fischer, J.J.
Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2)
J. Med. Chem.
55
3934-3944
2012
Homo sapiens
brenda
Riches, Z.; Liu, Y.; Berman, J.M.; Walia, G.; Collier, A.C.
The ontogeny and population variability of human hepatic dihydronicotinamide riboside: quinone oxidoreductase (NQO2)
J. Biochem. Mol. Toxicol.
31
e21921
2017
Homo sapiens (P16083), Homo sapiens
brenda
Schepers, A.; Shan, J.; Cox, A.; Huang, A.; Evans, H.; Walesky, C.; Fleming, H.; Goessling, W.; Bhatia, S.
Identification of NQO2 As a protein target in small molecule modulation of hepatocellular function
ACS Chem. Biol.
16
1770-1778
2021
Homo sapiens (P16083)
brenda
Zhang, J.; Zhou, Y.; Li, N.; Liu, W.; Liang, J.; Sun, Y.; Zhang, W.; Fang, R.; Huang, S.; Sun, Z.; Wang, Y.; He, Q.
Curcumol overcomes TRAIL resistance of non-small cell lung cancer by targeting NRH quinone oxidoreductase 2 (NQO2)
Adv. Sci. (Weinh.)
7
2002306
2020
Homo sapiens
brenda
Janda, E.; Martino, C.; Riillo, C.; Parafati, M.; Lascala, A.; Mollace, V.; Boutin, J.A.
Apigenin and luteolin regulate autophagy by targeting NRH-quinone oxidoreductase 2 in liver cells
Antioxidants (Basel)
10
776
2021
Homo sapiens (P16083)
brenda
Alnabulsi, S.; Hussein, B.; Santina, E.; Alsalahat, I.; Kadirvel, M.; Magwaza, R.N.; Bryce, R.A.; Schwalbe, C.H.; Baldwin, A.G.; Russo, I.; Stratford, I.J.; Freeman, S.
Evaluation of analogues of furan-amidines as inhibitors of NQO2
Bioorg. Med. Chem. Lett.
28
1292-1297
2018
Plasmodium falciparum, Homo sapiens (P16083)
brenda
Den Braver-Sewradj, S.; Den Braver, M.; Toorneman, R.; Van Leeuwen, S.; Zhang, Y.; Dekker, S.; Vermeulen, N.; Commandeur, J.; Vos, J.
Reduction and scavenging of chemically reactive drug metabolites by NAD(P)H quinone oxidoreductase 1 and NRH quinone oxidoreductase 2 and variability in hepatic concentrations
Chem. Res. Toxicol.
31
116-126
2018
Homo sapiens (P16083), Homo sapiens
brenda
Hussein, B.; Ikhmais, B.; Kadirvel, M.; Magwaza, R.N.; Halbert, G.; Bryce, R.A.; Stratford, I.J.; Freeman, S.
Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH quinoneoxidoreductase-2 (NQO2)
Eur. J. Med. Chem.
182
111649
2019
Homo sapiens (P16083)
brenda
Zhou, J.Q.; Zhu, S.Y.; He, Y.; Yu, K.D.
Association between a tri-allelic polymorphism in the estrogen metabolism oxidoreductase NRH quinone oxidoreductase 2 gene and risk of breast cancer by molecular subtype
Front. Genet.
12
658285
2021
Homo sapiens (P16083), Homo sapiens
brenda
Chhour, M.; Perio, P.; Gayon, R.; Ternet-Fontebasso, H.; Ferry, G.; Nepveu, F.; Boutin, J.A.; Sudor, J.; Reybier, K.
Association of NQO2 with UDP-glucuronosyltransferases reduces menadione toxicity in neuroblastoma cells
Front. Pharmacol.
12
660641
2021
Homo sapiens (P16083)
brenda